NCYT Novacyt S.A.
44.00GBp+10.00%Mkt Cap: 34.68M $P/E: —1d ago
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmenta…
Industry Peers
Medical Devices$170.98BUSDP/E 31.7
$111.40BUSDP/E 21.4
$106.71BUSDP/E 28.8
$61.14BUSDP/E 17.1
$49.80BUSDP/E 51.5
$46.31BUSDP/E 19.3
$31.47BUSDP/E 33.1
$29.46BUSDP/E 14.9
$22.91BUSDP/E 18.7
$23.60BUSDP/E 18.0
$20.34BUSDP/E 25.5
$17.13BUSDP/E 28.0
$17.11BUSDP/E 21.8
$12.49BUSDP/E 77.9
$11.25BUSDP/E 18.3
$10.51BUSD
$10.26BUSDP/E 19.6
$9.97BUSDP/E 28.3
$9.87BUSDP/E 46.7
$9.53BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Could Illumina’s Novacyt Collaboration Framework Quietly Reshape Its Clinical Sequencing Narrative (ILMN)? In September 2026, Novacyt S.A. announced it had entered into a five-year Master Collaboration Agreement with Illumina, creating a framework for separate project-based deals in product development and commercial collaboration. This structure gives Illumina a flexible way to tap Novacyt’s complementary expertise without committing upfront capital to specific programs, potentially broadening future genomic applications. We’ll now examine how this new Master Collaboration framework with... | ||
QQuartr | ||